|Bid||18.51 x 900|
|Ask||18.60 x 2200|
|Day's range||18.40 - 19.25|
|52-week range||0.95 - 32.99|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||09 Mar 2022 - 14 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||48.75|
LOS ANGELES, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022. The presentation will be available beginning on Monday, January 10, 2022 at 7:00 a.m. ET. The webcas
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
The analysts covering Aadi Bioscience, Inc. ( NASDAQ:AADI ) delivered a dose of negativity to shareholders today, by...